Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in Pemphigus
NCT06904040Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of cm313 in pemphigus vulgaris (PV) and pemphigus foliaceus (PF), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Efficacy evaluation at 52 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
cm313
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT06904040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904040.